33,776 Shares in KalVista Pharmaceuticals, Inc. $KALV Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 33,776 shares of the specialty pharmaceutical company’s stock, valued at approximately $680,000. Y Intercept Hong Kong Ltd owned about 0.07% of KalVista Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of KalVista Pharmaceuticals by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after purchasing an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. State Street Corp boosted its holdings in shares of KalVista Pharmaceuticals by 21.3% in the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock valued at $30,874,000 after buying an additional 336,195 shares during the period. Vestal Point Capital LP grew its position in shares of KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its position in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $27.00 on Tuesday. The company has a 50-day simple moving average of $26.90 and a 200-day simple moving average of $20.54. The firm has a market capitalization of $1.44 billion, a P/E ratio of -7.80 and a beta of -0.12. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $27.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. As a group, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Analyst Ratings Changes

KALV has been the topic of several research reports. Stifel Nicolaus increased their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wall Street Zen upgraded KalVista Pharmaceuticals to a “hold” rating in a research note on Saturday, June 13th. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Citizens Jmp cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Hold” and an average target price of $33.25.

Insider Activity

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,926 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total value of $292,598.28. Following the sale, the chief executive officer owned 479,989 shares in the company, valued at approximately $12,854,105.42. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,686 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the sale, the insider directly owned 142,547 shares in the company, valued at approximately $2,882,300.34. This trade represents a 1.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,971 shares of company stock worth $965,493 in the last quarter. Company insiders own 4.30% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.